2-bromo-N-(2-chloro-4-sulfamoylphenyl)acetamide | 920036-07-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-bromo-N-(2-chloro-4-sulfamoylphenyl)acetamide
• 英文别名: N-[4-(aminosulfonyl)-2-chlorophenyl]-2-bromoacetamide
• CAS: 920036-07-3
• 化学式: C₈H₈BrClN₂O₃S
• 分子量: 327.586
• InChiKey: HSAKTYABYGHJDQ-UHFFFAOYSA-N

物化性质

• 密度：
  1.854±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  97.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-bromo-N-(2-chloro-4-sulfamoylphenyl)acetamide 、 3-氯-5-[[2-氧代-4-(三氟甲基)-1,2-二氢吡啶-3-基]氧基]苯甲腈 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 N-[4-(aminosulfonyl)-2-chlorophenyl]-2-[3-(3-chloro-5-cyanophenoxy)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl]acetamide
  参考文献：
  名称：

  [EN] NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
  [FR] INHIBITEURS NON-NUCLÉOSIDIQUES DE LA TRANSCRIPTASE INVERSE

  摘要：

  公开号：

  WO2009067166A3
• 作为产物：
  描述：

  4-氨基-3-氯苯磺酰胺 、 溴乙酰溴 在 碳酸氢钠 作用下， 以 二氯甲烷 为溶剂， 反应 30.0h， 生成 2-bromo-N-(2-chloro-4-sulfamoylphenyl)acetamide
  参考文献：
  名称：

  HIV reverse transcriptase inhibitors

  摘要：

  具有以下结构的化合物：是HIV逆转录酶抑制剂，其中A、X、Y、Z、R1和R2在此处定义。这些化合物及其药用盐在抑制HIV逆转录酶、预防和治疗HIV感染以及预防、延缓AIDS发病和治疗方面具有用途。这些化合物及其盐可作为药物组成部分，可选择性地与其他抗病毒药物、免疫调节剂、抗生素或疫苗结合使用。

  公开号：

  US20070021442A1

文献信息

• NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
  申请人：Tucker Thomas J.

  公开号：US20100256181A1

  公开（公告）日：2010-10-07

  Heteroaromatic compounds of Formula (I) are HIV reverse transcriptase inhibitors, wherein ring A is: (ii-a), (ii-b), (ii-c), (ii-d), or (ii-e); and wherein n, L, M, U, X, Y, Z, R E , R F , R 1 , R 2A , R 2B , R 2C , R 3 , R 8 , R 9 and R 10 are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts and prodrugs are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts and prodrugs can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

  公式（I）的杂环芳香化合物是HIV反转录酶抑制剂，其中环A为：（ii-a）、（ii-b）、（ii-c）、（ii-d）或（ii-e）；其中n、L、M、U、X、Y、Z、RE、RF、R1、R2A、R2B、R2C、R3、R8、R9和R10的定义见本文。公式I的化合物及其药学上可接受的盐和前药在抑制HIV反转录酶、预防和治疗HIV感染以及预防、延迟发病或进展和治疗艾滋病方面有用。这些化合物及其盐和前药可作为药物组成部分，可与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。
• Non-nucleoside reverse transcriptase inhibitors
  申请人：Tucker Thomas J.

  公开号：US08404856B2

  公开（公告）日：2013-03-26

  Heteroaromatic compounds of Formula (I) are HIV reverse transcriptase inhibitors, wherein ring A is: (ii-a), (ii-b), (ii-c), (ii-d), or (ii-e); and wherein n, L, M, U, X, Y, Z, RE, RF, R1, R2A, R2B, R2C, R3, R8, R9 and R10 are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts and prodrugs are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts and prodrugs can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

  式(I)的杂环芳香化合物是HIV反转录酶抑制剂，其中环A为：(ii-a)、(ii-b)、(ii-c)、(ii-d)或(ii-e)；其中n、L、M、U、X、Y、Z、RE、RF、R1、R2A、R2B、R2C、R3、R8、R9和R10在此定义。式(I)的化合物及其药学上可接受的盐和前药在HIV反转录酶的抑制、预防和治疗HIV感染以及预防、延迟或治疗艾滋病方面有用。这些化合物及其盐和前药可用作制药组合物中的成分，可选择与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。
• Searching for novel scaffold of triazole non-nucleoside inhibitors of HIV-1 reverse transcriptase
  作者：Tomasz Frączek、Agata Paneth、Rafał Kamiński、Agnieszka Krakowiak、Piotr Paneth

  DOI：10.3109/14756366.2015.1039531

  日期：——

  Azoles are a promising class of the new generation of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs). From thousands of reported compounds, many possess the same basic structure of an aryl substituted azole ring linked by a thioglycolamide chain with another aromatic ring. In order to find novel extensions for this basic scaffold, we explored the 5-position substitution pattern of triazole NNRTIs using molecular docking followed by the synthesis of selected compounds. We found that heterocyclic substituents in the 5-position of the triazole ring are detrimental to the inhibitory activity of compounds with four-membered thioglycolamide linker and this substitution seems to be viable only for compounds with shorter two-membered linker. Promising compound, N-(4-carboxy-2-chlorophenyl)-2-((4-benzyl-5-methyl-4H-1,2,4-triazol-3-yl)sulfanyl)acetamide, with potent inhibitory activity and acceptable aqueous solubility has been identified in this study that could serve as lead scaffold for the development of novel water-soluble salts of triazole NNRTIs.
• The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations
  作者：Thomas J. Tucker、Sandeep Saggar、John T. Sisko、Robert M. Tynebor、Theresa M. Williams、Peter J. Felock、Jessica A. Flynn、Ming-Tain Lai、Yuexia Liang、Georgia McGaughey、Meiquing Liu、Mike Miller、Gregory Moyer、Vandna Munshi、Rebecca Perlow-Poehnelt、Sridhar Prasad、Rosa Sanchez、Maricel Torrent、Joseph P. Vacca、Bang-Lin Wan、Youwei Yan

  DOI：10.1016/j.bmcl.2008.03.064

  日期：2008.5

  Using a combination of traditional Medicinal Chemistry/SAR analysis, crystallography, and molecular modeling, we have designed and synthesized a series of novel, highly potent NNRTIs that possess broad antiviral activity against a number of key clinical mutations. (C) 2008 Elsevier Ltd. All rights reserved.
• HIV REVERSE TRANSCRIPTASE INHIBITORS
  申请人：Merck & Co., Inc.

  公开号：EP1910360A2

  公开（公告）日：2008-04-16